Last reviewed · How we verify

NCT04965649: TIPHI

Is There an Association Between Innate CD8+ T Cells and the Evolution of Tyrosine Kinase Inhibitor Resistance Mutations in Phi+ Hematological Malignancies.

Status unknown Last updated 30 August 2023
What this trial tests

trial testing Phenotyping of total and innate CD8+T cells by flow cytometry in Leukemia in 30 participants. Status unknown.

Timeline
1 January 2021
Primary endpoint
1 July 2024
1 January 2025

Quick facts

Lead sponsorCentre Hospitalier Universitaire de Nīmes
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment30
Start date1 January 2021
Primary completion1 July 2024
Estimated completion1 January 2025
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire de Nīmes

Who can join

18 and older, any sex, with Leukemia or Myelogenous Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this project is to test whether low levels of BcrAbl1, despite the presence of resistance mutations, are related to high levels of innate CD8+ T cells, in the hypothesis that these cells have an anti-tumor role. This research aims to investigate: * An association between the rate of innate CD8+ T cells and the evolution of Phi+ pathologies (Chronic Myeloid Leukemia and Philadelphia chromosome-positive Acute lymphocytic leukemia (Phi+ ALL) carrying a resistance mutation, according to the ELN 2013 and Phi LMC recommendations. * An association between the level of innate CD8+ T cells and the expansion of TKI resistance clones, assessed as the number of BcrAbl1 copies carrying the mutation relative to the number of Abl1 copies.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The expanding Pandora's toolbox of CD8<sup>+</sup>T cell: from transcriptional control to metabolic firing.
    Wu J, Lu Z, Zhao H, Lu M, et al · · 2023 · cited 6× · PMID 38082437 · DOI 10.1186/s12967-023-04775-3

Verify or expand the search:

Other recruiting trials for Leukemia

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire de Nīmes trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04965649.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing